688203 Zhejiang Hisun Biomaterials
- 9.16
- -0.41-4.28%
Zhejiang Hisun Biomaterials News
Haizheng Raw Materials (688203.SH) announced first-quarter results, net profit of 6.9085 million yuan, an increase of 66.06% year-on-year
Haizheng Raw Materials (688203.SH) released its report for the first quarter of 2024. The company's revenue was 192 million yuan...
Haizheng Raw Materials (688203): Revenue and sales bucked the trend and increased “price for volume” to expand market share
The incident described the company released its 2023 annual report. In 2023, it achieved total operating revenue of 753 million yuan, an increase of 24.4% year on year; net profit to mother was 43.549 million yuan, down 7.4% year on year; minus 40 percent of non-net profit
Zhejiang Hisun BiomaterialsLtd's (SHSE:688203) Weak Earnings May Only Reveal A Part Of The Whole Picture
The subdued market reaction suggests that Zhejiang Hisun Biomaterials Co.Ltd.'s (SHSE:688203) recent earnings didn't contain any surprises. However, we believe that investors should be aware of some
Haizheng Raw Materials (688203): Subsidiary projects achieve production volume in exchange for price
There was a slight decline in full-year results. The company recently released its 2023 annual report. It achieved annual revenue of 753 million yuan, a year-on-year increase of 24.43%, and achieved net profit of 43.55 million yuan to mother, a year-on-year decrease of 7.41%, after deducting non-return to mother
Haizheng Raw Materials (688203.SH) reported 2023 annual results, with net profit of 43.549 million yuan, a year-on-year decrease of 7.41%. It is planned to distribute 0.8 yuan for every 10 shares
Haizheng Raw Materials (688203.SH) released its 2023 annual report. The company achieved operating income of 7 during the reporting period...
“Price for volume” boosts market share in 2023 Haizheng Raw Materials's revenue increased 24.43% year-on-year
① The company adjusted its marketing strategy in a timely manner during the reporting period, and sales and revenue grew in 2023. ② In terms of cost control, the company said that on the one hand, the polylactic acid production process is being continuously optimized, production capacity is continuously being expanded, and production costs are gradually being reduced; on the other hand, the cost of terminal products is further reduced through composite modification of materials, etc.
Haizheng Raw Materials (688203.SH) performance report: 2023 net profit of 43.1129 million yuan, a year-on-year decrease of 8.37%
Gelonghui, Feb. 19: Haizheng Raw Materials (688203.SH) announced its 2023 annual performance report. During the reporting period, the company achieved total operating revenue of 75,3317 million yuan, an increase of 24.43% year on year; realized total profit of 53,0783 million yuan, up 0.96% year on year; realized net profit attributable to owners of the parent company of 43.1129 million yuan, a year-on-year decrease of 8.37%; realized net profit attributable to owners after deducting non-recurring profit and loss of 20.23% year on year. Facing external macroeconomic influences and competition in the polylactic acid industry
Zhejiang Hisun BiomaterialsLtd (SHSE:688203) May Have Issues Allocating Its Capital
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for? One common approach is to try and find a company with returns on capital employed
Haizheng Raw Materials (688203.SH) will list and circulate 39.079 million restricted shares on February 19
Haizheng Raw Materials (688203.SH) announced that the total number of shares in circulation in the company's current stock listing is 39.07.69 million shares,...
Haizheng Biotech (688203.SH): The main business is R&D, production and sales of polylactic acid resins, which are bio-based degradable materials
Gelonghui November 17丨Haizheng Shengcai (688203.SH) stated on the investor interactive platform that the company's main business is R&D, production and sales of polylactic acid resin, a bio-based degradable material. Toughened and modified polylactic acid materials have good processing performance. At the same time, they have the characteristics of slow crystallization rate, appropriate melting temperature, and no irritating gases at high temperatures. They have become ideal molding materials for 3D printing, showing good development potential in automotive parts and other fields.
Haizheng Biotech (688203): Revenue and profit improved quarter by quarter, “price for volume” market share steadily increased
Event description The company released the 2023Q3 quarterly report. The first three quarters of 2023 achieved revenue of 550 million yuan, an increase of 14.9% over the previous year; net profit of 37 million yuan, a decrease of 11.3% over the previous year; and deducted non-return net profit
Haizheng Biomaterials (688203.SH) released the first three quarter results, with net profit of 37.283 million yuan, a year-on-year decrease of 11.30%
Haizheng Biomaterials (688203.SH) released its report for the first three quarters of 2023, with revenue of 550 million yuan, year-on-year...
Haizheng Biomaterials (688203.SH): Demand for polylactic acid products will usher in new growth points
GLONGHUI September 4 丨 Some investors asked Haizheng Biomaterials (688203.SH): Which markets account for high demand among downstream applications? Haizheng Biotech replied: Airline tableware, airport stores, and some leading brand chain stores have begun replacing them with polylactic acid products. With the recovery of China's economy and movement of people, demand for polylactic acid products will usher in a new growth point.
Haizheng Biomedical Materials (688203.SH): Fundraising project under construction
Gelonghui September 4 丨 Some investors asked Haizheng Biomaterials (688203.SH): Will the estimated commissioning time of the 150,000-ton polylactic acid fundraising project change due to market reasons? Haizheng Biomaterials replied: The fundraising project is under construction. If there are any changes or adjustments, the company will carry out the corresponding review procedures and disclose the information. Please pay attention to the company's related announcements.
Haizheng Biomaterials (688203.SH): The field of express packaging bags is currently in the sample stage
GLONGHUI September 4 丨 Some investors asked Haizheng Biomaterials (688203.SH): How is the express bag project progressing? Will there be enough release this year? Haizheng Biotech replied: The field of express packaging bags is currently in the trial stage. Express delivery companies have already purchased some express bags from downstream product manufacturers and are being promoted in various pilots. In the later stages, there are also processes such as technical feedback, product quality verification, cost accounting, and evaluation of local policies and regulations. It is expected that it will only be possible to gradually release the volume next year or the year after.
Haizheng Raw Materials (688203.SH): The price of raw lactic acid has dropped by a certain margin compared to the same period last year
GLONGHUI September 4 丨 Some investors asked Haizheng Biomaterials (688203.SH): How does the price of raw lactic acid compare with the same period last year? Looking ahead to the third quarter, will there be a further drop in prices for raw materials? Haizheng Raw Materials replied: The price of the raw material lactic acid has dropped by a certain margin compared to the same period last year. Regarding raw material procurement costs in the third quarter, we expect them to remain stable.
Haizheng Biomaterials (688203.SH): The Heinor Phase II production line has been commissioned for half a year
GLONGHUI September 4 丨 Some investors asked Haizheng Biomaterials (688203.SH): What is the current commencement status of the new Heinor Phase II production line and plans for future production capacity growth? Haizheng Biomaterials replied: The Heinor Phase II production line has been commissioned for half a year and has continuous production capacity. Production capacity should be climbing faster than the first phase of the production line. It is expected that the production capacity of the design capacity can be reached in the second half of the year. The release of overall production capacity needs to be combined with market demand conditions.
Haizheng Raw Materials (688203.SH): According to previous experience, the third quarter is the peak season for domestic consumption
GLONGHUI September 4 丨 Some investors asked Haizheng Biomaterials (688203.SH): Are the company's sales seasonal? Haizheng Raw Materials replied: According to the experience of previous years, the third quarter was the peak season for domestic consumption, and the fourth quarter was the peak season for foreign consumption.
Haizheng Biomass (688203.SH): Haizheng Biomass's sales volume of polylactic acid in the first half of the year was 17,700 tons
GLONGHUI September 4 丨 Some investors asked Haizheng Biomaterials (688203.SH): How much was Haizheng Biotech's sales volume of polylactic acid in the first half of the year? Haizheng Biomass replied: Haizheng Biomass's sales volume of polylactic acid in the first half of the year was 17,700 tons, an increase of 23% over the previous year.
Haizheng Biomaterials (688203.SH): The entire market for degradable materials is a process of gradual growth
GLONGHUI September 4 丨 Some investors asked Haizheng Biomaterials (688203.SH): The company's views on future biodegradable packaging materials, when is the industry's inflection point expected to occur? Haizheng Biomaterials replied: We believe that the entire market for degradable materials is a process of gradual growth. The market should advance gradually; there will not be a sudden inflection point leading to explosive growth in the entire market.
Analysis
Price Target
No Data
